H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Zura Bio (ZURA) to $3 from $5 and keeps a Buy rating on the shares following the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA:
- Zura Bio price target lowered to $19 from $20 at Oppenheimer
- Zura Bio Limited: 2024 Financial Results and Strategic Progress
- ZURA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Zura Bio’s Growth Potential: Buy Rating Backed by Key Catalysts and Phase 2 Developments
- Zura Bio to Participate in Global Healthcare Conference